Press Release

Global Dehydrated Culture Media & Microbiology Reference Materials Market Outlook 2033: Pheonix Research Puts the Market at USD 1.40 Billion Today and USD 2.30 Billion by 2033, With a Third of the Growth Coming From Price

· Food & Beverages

Pheonix Research publishes its 2026–2033 forecast for dehydrated culture media and microbiology reference materials

LONDON, 21 November 2026 — Pheonix Research today published its market report on dehydrated culture media and microbiology reference materials, valuing the global market at USD 1,400.0 million in 2025 and forecasting USD 2,297.0 million in 2033, a compound annual growth rate of 6.38 per cent.

The report separates the market into two articles that share a laboratory bench but not a pricing mechanism. Dehydrated culture media — the powdered and granulated formulations a laboratory reconstitutes into plates and broths — is USD 1,210.0 million and grows at 6.02 per cent on 3.84 per cent volume growth and 2.10 per cent price. Microbiology reference materials — the qualified and certified strains against which media performance is demonstrated — is USD 190.0 million and grows at 8.50 per cent, moving from 13.57 per cent to 15.89 per cent of total market value.

Of USD 897.0 million of growth, a third is price

Pheonix decomposes the USD 897.0 million added between 2025 and 2033 into three components: USD 426.0 million (47.5 per cent) from more medium at the 2025 price, USD 296.1 million (33.0 per cent) from a dearer medium including the volume–price interaction, and USD 175.0 million (19.5 per cent) from reference materials growing both in volume and in price.

That price share is unusual in a testing-adjacent market and the report explains it structurally rather than competitively. ISO 11133 fixes a medium’s productivity, selectivity and specificity against named control strains and does not price it, so the price is disciplined by switching cost — a laboratory that changes supplier must re-validate a documented performance claim. The 2.10 per cent annual price in the model sits below both disclosed reads available: HiMedia Laboratories improved realisation by 5 per cent in fiscal 2025, and bioMérieux took two percentage points of price in microbiology. The published price share is therefore a floor.

ISO 11133 Edition 2 is under publication

On the ISO project record, ISO 11133 Edition 2 is at stage 60.00, under publication, with the final production step dated 20 October 2026, replacing the 2014 edition and integrating the 2018 and 2020 amendments. It adds Annex F on reference culture media, Annex K on preparing standardised test suspensions and storing them below −70 °C, Annex L on pH measurement, Annex M on evaluating buffered peptone water, and a revision of Annex G on control strains.

Pheonix expects the effect to register as a re-validation wave across 2027 and 2028, because laboratories accredited to ISO/IEC 17025 must refresh the validation evidence on which their methods rest when the normative basis changes.

Two owners reached opposite conclusions in the same year

On 27 April 2026 Thermo Fisher Scientific signed a definitive agreement to sell its microbiology business — antimicrobial susceptibility testing and culture media for clinical, pharmaceutical and food safety testing — to Astorg for approximately USD 1.075 billion. The business generated USD 645 million of revenue in 2025, making the headline price 1.67 times sales and 1.59 times on the cash element alone.

In the same period bioMérieux, which reports microbiology at 33 per cent of EUR 4,070 million of 2025 sales, guided that line to 6 to 8 per cent compound growth between 2024 and 2028.

The report’s conclusion is that neither owner is wrong about the category, and that the reconciliation is in the composition of what each is selling. One is selling a business dominated by the powder and by instruments, where substitution is possible and the specification is public. The other is compounding an instrumented workflow in which the medium is one input to a validated system. On Pheonix’s reading they are describing different halves of the same market, and the half growing faster is the one that is smaller, less disclosed and more profitable.

What the report declines to publish

Pheonix states on the page that the base-year value is a construct: only one supplier discloses revenue because of this category, and it did so in order to leave it. The report publishes a band of USD 1,190 million to USD 1,625 million around the USD 1,400.0 million headline rather than a single unqualified figure.

The report also publishes no regional split, stating that the model carries no geography and that inferring one from secondary commentary would produce a table that cannot be defended; no market-share table, because no disclosed revenue line maps onto the definition used; and no transaction multiple for the reference-material layer, because no transaction with a separable revenue line in that layer has been disclosed.

Two companies named in the report carry no entity link because no durable public identifier exists for them: HiMedia Laboratories and Microbiologics. The report says so rather than linking to an approximation.

About the report

The report runs to six chapters covering the value chain, technology and innovation, the competitive landscape, the regulatory landscape, investment activity and market risk, with fifteen table-of-contents entries, four figures with sourced captions, ten companies, ten related published reports and full field-level metadata. It is built 70 per cent on secondary regulatory and corporate sources and 30 per cent on Pheonix’s own analysis and interview programme.

The full report is available at pheonixresearch.com.

Media contact

Pheonix Research — research desk. Gaurav Chaudhary, author.